BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewis JH. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond. Clin Gastroenterol Hepatol 2015;13:2173-89.e8. [PMID: 26116527 DOI: 10.1016/j.cgh.2015.06.017] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Di Zeo-sánchez DE, Segovia-zafra A, Matilla-cabello G, Pinazo-bandera JM, Andrade RJ, Lucena MI, Villanueva-paz M. Modeling drug-induced liver injury: current status and future prospects. Expert Opinion on Drug Metabolism & Toxicology. [DOI: 10.1080/17425255.2022.2122810] [Reference Citation Analysis]
2 Jang BK. Are Angiotensin II Receptor Blockers Really Safe From Aminotransferase Elevation or Drug-Induced Liver Injury? J Korean Med Sci 2022;37:e261. [PMID: 35996936 DOI: 10.3346/jkms.2022.37.e261] [Reference Citation Analysis]
3 Calistri L, Rastrelli V, Nardi C, Maraghelli D, Vidali S, Pietragalla M, Colagrande S. Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis. World J Gastroenterol 2021; 27(46): 7866-7893 [DOI: 10.3748/wjg.v27.i46.7866] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lewis JH, Cottu PH, Lehr M, Dick E, Shearer T, Rencher W, Bexon AS, Campone M, Varga A, Italiano A. Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity. Drug Saf 2020;43:1045-55. [PMID: 32594454 DOI: 10.1007/s40264-020-00964-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 van Rheenen PF. Managing abnormal liver tests in children with inflammatory bowel disease. Curr Opin Pediatr 2021;33:521-9. [PMID: 34261897 DOI: 10.1097/MOP.0000000000001045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Bartl S, Dinkhauser P, Hofer H. Medikamentös-toxische Leberschädigung und Immuncheckpointinhibitor-induzierte Hepatitis. J Gastroenterol Hepatol Erkr 2021;19:34-43. [DOI: 10.1007/s41971-021-00100-1] [Reference Citation Analysis]
7 Itay A, Yoav L, Ariel K, Shoshana Z, Ina G, Elad R, Shimon S, Tali B, David E K. Characterization of patients diagnosed with drug-induced liver injury. Arch Clin Gastroenterol 2021. [DOI: 10.17352/2455-2283.000095] [Reference Citation Analysis]
8 Kumar N, Surani S, Udeani G, Mathew S, John S, Sajan S, Mishra J. Drug-induced liver injury and prospect of cytokine based therapy; A focus on IL-2 based therapies. Life Sci 2021;278:119544. [PMID: 33945827 DOI: 10.1016/j.lfs.2021.119544] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
9 Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, Wagner AJ, Pousa AL, Druta M, Lin CC, Baba HA, Choi Y, Wang Q, Shuster DE, Bauer S. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist 2021;26:e863-73. [PMID: 33289960 DOI: 10.1002/onco.13629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
10 Huang Y, Zhao X, Zhang ZT, Chen SS, Li SS, Shi Z, Jing J, Huang A, Guo YM, Bai ZF, Zou ZS, Xiao XH, Wang JB, Niu M. Metabolomics Profiling and Diagnosis Biomarkers Searching for Drug-Induced Liver Injury Implicated to Polygonum multiflorum: A Cross-Sectional Cohort Study.Front Med (Lausanne). 2020;7:592434. [PMID: 33330552 DOI: 10.3389/fmed.2020.592434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Lewis JH, Jadoul M, Block GA, Chin MP, Ferguson DA, Goldsberry A, Meyer CJ, O'Grady M, Pergola PE, Reisman SA, Wigley WC, Chertow GM. Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD. Clin Transl Sci 2021;14:299-309. [PMID: 32860734 DOI: 10.1111/cts.12868] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ke L, Lu C, Shen R, Lu T, Ma B, Hua Y. Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010-2019). Front Pharmacol 2020;11:842. [PMID: 32581801 DOI: 10.3389/fphar.2020.00842] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 14.3] [Reference Citation Analysis]
13 Lewis JH, Seeff LB. The Origins of the Modern-Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman. Clin Liver Dis (Hoboken) 2020;15:S25-36. [PMID: 32140211 DOI: 10.1002/cld.856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Pan G. Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity. Adv Exp Med Biol 2019;1141:293-340. [PMID: 31571168 DOI: 10.1007/978-981-13-7647-4_6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
15 Timmer A, de Sordi D, Kappen S, Kohse KP, Schink T, Perez-Gutthann S, Jacquot E, Deltour N, Pladevall M. Validity of hospital ICD-10-GM codes to identify acute liver injury in Germany. Pharmacoepidemiol Drug Saf 2019;28:1344-52. [PMID: 31373108 DOI: 10.1002/pds.4855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Shavadia JS, Sharma A, Gu X, Neaton J, Deleve L, Holmes D, Home P, Eckel RH, Watkins PB, Granger CB. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program. Clinical Trials 2019;16:253-62. [DOI: 10.1177/1740774519836766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
17 Spernovasilis N, Kofteridis DP. Pre-Existing Liver Disease and Toxicity of Antifungals. J Fungi (Basel) 2018;4:E133. [PMID: 30544724 DOI: 10.3390/jof4040133] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
18 Teschke R. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.Expert Opin Drug Metab Toxicol. 2018;14:1169-1187. [PMID: 30354694 DOI: 10.1080/17425255.2018.1539077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
19 Antonazzo IC, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E, Muratori L, De Ponti F, Raschi E. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler 2019;25:1633-40. [DOI: 10.1177/1352458518799598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
20 Benesic A, Rotter I, Dragoi D, Weber S, Leitl A, Buchholtz ML, Gerbes AL. Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol 2018;16:1488-1494.e5. [PMID: 29723689 DOI: 10.1016/j.cgh.2018.04.049] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
21 Ye JH, Ho YF, On AW, Chen WW, Huang YM, Huang WI, Tang YW. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone. Int J Clin Pharm 2018;40:911-20. [PMID: 30051228 DOI: 10.1007/s11096-018-0698-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
22 Thomas AM, Lewis JH. Nonacetaminophen Drug-Induced Acute Liver Failure. Clin Liver Dis 2018;22:301-24. [PMID: 29605068 DOI: 10.1016/j.cld.2018.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gordon-Walker TT. Editorial: alleviating the itch-the safety of rifampicin in the real world. Aliment Pharmacol Ther 2018;47:1332-3. [PMID: 29644731 DOI: 10.1111/apt.14615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Tan EH, Low EXS, Dan YY, Tai BC. Systematic review and meta-analysis of algorithms used to identify drug-induced liver injury (DILI) in health record databases. Liver Int 2018;38:742-53. [PMID: 29193566 DOI: 10.1111/liv.13646] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
25 D'Amico E, Patti F, Zanghì A, Lo Fermo S, Chisari CG, Zappia M. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Rev Clin Pharmacol 2018;11:531-6. [PMID: 29521113 DOI: 10.1080/17512433.2018.1449643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Norman BH, Fisher MJ, Schiffler MA, Kuklish SL, Hughes NE, Czeskis BA, Cassidy KC, Abraham TL, Alberts JJ, Luffer-atlas D. Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury. J Med Chem 2018;61:2041-51. [DOI: 10.1021/acs.jmedchem.7b01806] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
27 Deng R. Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches. Methods in Pharmacology and Toxicology 2018. [DOI: 10.1007/978-1-4939-7677-5_15] [Reference Citation Analysis]
28 Ju C, Phillips E, Holt M, Gao Y, Lammert C. The Adaptive Immune System and Liver Toxicity. Comprehensive Toxicology 2018. [DOI: 10.1016/b978-0-12-801238-3.95663-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Lewis JH. Drug-Induced and Toxic Liver Disease. Handbook of Liver Disease 2018. [DOI: 10.1016/b978-0-323-47874-8.00010-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Light DS, Aleo MD, Kenna JG. Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge. Methods in Pharmacology and Toxicology 2018. [DOI: 10.1007/978-1-4939-7677-5_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 2017;66:1727-38. [PMID: 28586116 DOI: 10.1002/hep.29306] [Cited by in Crossref: 341] [Cited by in F6Publishing: 307] [Article Influence: 56.8] [Reference Citation Analysis]
32 Taneja S, Kumar P, Rathi S, Duseja A, Singh V, Dhiman RK, Chawla YK. Acute Liver Failure Due to Etodolac, a Selective Cycloxygenase- 2 (COX -2) Inhibitor Non-Steroidal Anti-Inflammatory Drug Established by RUCAM-Based Causality Assessment. Ann Hepatol 2017;16:818-21. [PMID: 28809737 DOI: 10.5604/01.3001.0010.2829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Dumortier J, Cottin J, Lavie C, Guillaud O, Hervieu V, Chambon-augoyard C, Scoazec J, Vukusic S, Vial T. Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey. Clinics and Research in Hepatology and Gastroenterology 2017;41:497-501. [DOI: 10.1016/j.clinre.2017.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
34 Teschke R, Schulze J, Eickhoff A, Danan G. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? Int J Mol Sci. 2017;18:E803. [PMID: 28398242 DOI: 10.3390/ijms18040803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
35 Alempijevic T, Zec S, Milosavljevic T. Drug-induced liver injury: Do we know everything? World J Hepatol 2017; 9(10): 491-502 [PMID: 28443154 DOI: 10.4254/wjh.v9.i10.491] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 7.8] [Reference Citation Analysis]
36 Stieger B, Mahdi ZM. Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease. J Pharm Sci 2017;106:2295-301. [PMID: 28385542 DOI: 10.1016/j.xphs.2017.03.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
37 Gonzalez HC, Jafri SM, Gordon SC. Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems. Clin Liver Dis 2017;21:163-80. [PMID: 27842770 DOI: 10.1016/j.cld.2016.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
38 Stine JG, Chalasani NP. Drug Hepatotoxicity: Environmental Factors. Clin Liver Dis 2017;21:103-13. [PMID: 27842766 DOI: 10.1016/j.cld.2016.08.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
39 Raschi E, De Ponti F. Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol 2017; 9(1): 30-37 [PMID: 28105256 DOI: 10.4254/wjh.v9.i1.30] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
40 Daly A. Drug-Induced Liver Disease. Comprehensive Medicinal Chemistry III 2017. [DOI: 10.1016/b978-0-12-409547-2.12382-0] [Reference Citation Analysis]
41 Overby CL, Raschid L, Liu H. Exploiting HPO to Predict a Ranked List of Phenotype Categories for LiverTox Case Reports. Data Management and Analytics for Medicine and Healthcare 2017. [DOI: 10.1007/978-3-319-57741-8_1] [Reference Citation Analysis]
42 Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, Lin L, Xie WF. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis 2016;17:618-27. [PMID: 27426618 DOI: 10.1111/1751-2980.12383] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
43 Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opinion on Drug Metabolism & Toxicology 2016;12:1291-301. [DOI: 10.1080/17425255.2016.1211110] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
44 Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines. 2016;3:18. [PMID: 28930128 DOI: 10.3390/medicines3030018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
45 Kakisaka K, Kataoka K, Suzuki Y, Okada Y, Yoshida Y, Kuroda H, Takikawa Y. Necrotic cell death and suppression of T-cell immunity characterized acute liver failure due to drug-induced liver injury. Cytokine 2016;86:21-8. [PMID: 27442007 DOI: 10.1016/j.cyto.2016.07.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
46 Lee SJ, Lee YJ, Park KK. The pathogenesis of drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2016;10:1175-85. [PMID: 27248313 DOI: 10.1080/17474124.2016.1196133] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
47 Sarges P, Steinberg JM, Lewis JH. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Saf 2016;39:801-21. [DOI: 10.1007/s40264-016-0427-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 7.9] [Reference Citation Analysis]
48 Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016;10:517-536. [PMID: 26633044 DOI: 10.1586/17474124.2016.1127756] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
49 Rathi S, Dhiman RK. Hepatobiliary Quiz (Answers)-16 (2015). J Clin Exp Hepatol 2015;5:357-60. [PMID: 26900280 DOI: 10.1016/j.jceh.2015.12.002] [Reference Citation Analysis]
50 Wang W, Shi Q, Mattes WB, Mendrick DL, Yang X. Translating extracellular microRNA into clinical biomarkers for drug-induced toxicity: from high-throughput profiling to validation. Biomark Med 2015;9:1177-88. [PMID: 26501984 DOI: 10.2217/bmm.15.86] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]